Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas

We investigated a therapeutic strategy for recurrent malignant gliomas using mesenchymal stem cells (MSC), expressing cytosine deaminase (CD), and prodrug 5-Fluorocytosine (5-FC) as a more specific and less toxic option. MSCs are emerging as a novel cell therapeutic agent with a cancer-targeting pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Taemoon, Na, Juri, Kim, Young-il, Chang, Da-Young, Kim, Young Il, Kim, Hyeonjin, Moon, Ho Eun, Kang, Keon Wook, Lee, Dong Soo, Chung, June-Key, Kim, Sung-Soo, Suh-Kim, Haeyoung, Paek, Sun Ha, Youn, Hyewon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955049/
https://www.ncbi.nlm.nih.gov/pubmed/27446484
http://dx.doi.org/10.7150/thno.14158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955049/
https://www.ncbi.nlm.nih.gov/pubmed/27446484
http://dx.doi.org/10.7150/thno.14158

Ejemplares similares